The study team, led by researchers at the Reproductive Medicine Center of Sun Yat-Sen Memorial Hospital in Guangzhou, together with colleagues at Shenzhen Baoan Women’s and Children’s Hospital and several other institutions, analyzed data from 1,042 women who had experienced at least one miscarriage. Unlike most previous work, which concentrated almost exclusively on fasting measurements of insulin resistance, the investigators deliberately examined two distinct metabolic states: fasting insulin resistance, captured by the homeostasis model assessment of insulin resistance known as HOMA-IR, and postprandial insulin resistance, the dynamic metabolic condition that emerges after eating and that was assessed using the Stumvoll Insulin Sensitivity Index, or ISI-Stumvoll.

The technical distinction matters. HOMA-IR is calculated from fasting glucose and fasting insulin levels and reflects how efficiently the body’s tissues respond to insulin in the basal, overnight-fasted state. The Stumvoll index, by contrast, is derived from values obtained during an oral glucose tolerance test and estimates insulin sensitivity under the post-meal conditions that dominate everyday physiology. Postprandial insulin resistance has been flagged in the metabolic literature as an early marker of dysmetabolism, sometimes appearing before fasting measures become abnormal, yet its relationship to pregnancy outcomes had remained largely unexplored until now.

Using multivariable logistic regression models that adjusted for potential confounding factors, the researchers found that higher HOMA-IR values were associated with a significantly increased risk of miscarriage, with an odds ratio of 1.97 and a 95 percent confidence interval spanning 1.33 to 2.94, a result that reached statistical significance at P less than 0.001. In other words, women whose fasting insulin resistance was elevated faced nearly double the odds of losing the pregnancy compared with those whose fasting metabolism appeared healthier. Conversely, higher scores on the Stumvoll Insulin Sensitivity Index, which indicate greater insulin sensitivity, were associated with a reduced risk of miscarriage, with an odds ratio of 0.66 and a confidence interval of 0.45 to 0.98, significant at P equal to 0.038.

To probe the shape of these relationships more finely, the team employed restricted cubic spline analysis, a statistical technique that allows the association between a continuous exposure and an outcome to take on nonlinear forms rather than forcing a straight line. The results revealed a positive monotonic relationship between both HOMA-IR and the Stumvoll index and miscarriage risk, meaning risk rose steadily across the range of values without evidence of a threshold effect or a U-shaped curve. Formal tests for nonlinearity returned P values of 0.130 for HOMA-IR and 0.940 for the Stumvoll index, indicating no statistically significant departure from a linear trend for either marker.

Perhaps the most clinically consequential finding emerged when the researchers combined the two indicators. Women classified as insulin resistant by either HOMA-IR or the Stumvoll index—meaning they showed abnormal metabolism in the fasting state, the postprandial state, or both—had a significantly higher risk of miscarriage than women who were insulin sensitive on both measures. The combined classification yielded an odds ratio of 1.88 with a 95 percent confidence interval of 1.43 to 2.49 and a P value below 0.001. According to the authors, pairing the fasting and postprandial indicators was able to identify more individuals at elevated risk than either marker alone, a point with clear implications for how clinicians might screen women with recurrent or prior pregnancy loss.

The biological plausibility of a metabolic link to miscarriage is supported by a substantial body of prior research. Insulin resistance has been shown to exert direct toxic effects on human placental tissue, an effect that experimental work suggests can be mitigated by metformin. Animal studies have demonstrated that maternal insulin resistance causes oxidative stress and mitochondrial dysfunction in oocytes, potentially compromising egg quality from the very start of a pregnancy. Hyperinsulinemia, the compensatory surge of insulin that accompanies resistance, has been shown in mouse models to impair endometrial receptivity in early pregnancy, undermining the delicate dialogue between embryo and uterine lining. In women with unexplained recurrent pregnancy loss, insulin resistance has been associated with impaired decidualization—the transformation of the uterine lining that is essential for embryo implantation—along with altered expression of signaling molecules within the decidua itself.

Earlier clinical studies had already hinted at the connection. Research on patients undergoing assisted reproduction technology found that insulin resistance increased the risk of spontaneous abortion after treatment, and subsequent work in women with polycystic ovary syndrome undergoing in vitro fertilization linked insulin resistance to poorer ovarian sensitivity and adverse pregnancy outcomes. Systematic reviews and meta-analyses have identified high body mass index and insulin resistance as risk factors for spontaneous abortion in polycystic ovary syndrome patients receiving assisted reproductive treatment. What distinguished these earlier investigations, and what limited their reach, was their focus on infertility populations. The new study extends the association to women with miscarriage history in a broader clinical context, addressing what the authors describe as a critical gap in knowledge about insulin resistance and reproductive health outside fertility clinics.

The retrospective cohort design carries inherent limitations that the authors and outside observers will need to weigh. Because the data were collected from medical records at Sun Yat-Sen Memorial Hospital and Shenzhen Baoan Women’s and Children’s Hospital rather than through prospective follow-up, the analysis can establish association but not causation, and residual confounding by unmeasured factors—such as detailed dietary patterns, physical activity, or genetic predisposition—cannot be excluded. The study protocols were approved by the Ethics Committee for Clinical Research of Sun Yat-Sen Memorial Hospital, and the authors note that informed consent could not be obtained given the retrospective nature of the work. The underlying data are available from the corresponding author upon reasonable request, and the research was supported by the Guangdong Natural Science Foundation and the Yixian Clinical Research 5010 Project of Sun Yat-Sen Memorial Hospital.

Even with those caveats, the implications are difficult to ignore. Miscarriage is the most common complication of pregnancy, imposing substantial epidemiological, physical, psychological, and economic costs, and it carries significant consequences for mental health, including depression and anxiety following early pregnancy loss. If simple, widely available metabolic tests—fasting glucose and insulin for HOMA-IR, standard oral glucose tolerance values for the Stumvoll index—can flag women at heightened risk before conception, clinicians gain a potential window for intervention through lifestyle modification or insulin-sensitizing therapy. The authors conclude that both the fasting indicator HOMA-IR and the postprandial indicator ISI-Stumvoll were associated with miscarriage in women with a history of pregnancy loss, and that combining the two identifies more high-risk individuals. For the millions of women who endure the heartbreak of recurrent pregnancy loss, a routine blood test that reveals a modifiable risk factor would represent a meaningful step toward turning metabolic insight into reproductive hope.

Subject of Research: The association between fasting and postprandial insulin resistance patterns and miscarriage risk in women with a history of pregnancy loss.

Article Title: Association of Different Patterns of Insulin Resistance With Miscarriage in Population With Miscarriage History: a Multicenter Retrospective Cohort Study

Article References: Tang, J., Yu, Y., Zhang, J., Gan, Y., Yuan, S., Wang, Z., Ji, X., Mo, H., Zhang, Q., Shi, Y., & Chen, H. (2026). Association of Different Patterns of Insulin Resistance With Miscarriage in Population With Miscarriage History: a Multicenter Retrospective Cohort Study. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02193-6

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02193-6

Keywords: insulin resistance, miscarriage, HOMA-IR, Stumvoll Insulin Sensitivity Index, postprandial insulin resistance, recurrent pregnancy loss, reproductive medicine, glucose metabolism, endometrial receptivity, retrospective cohort study, Reproductive Sciences, polycystic ovary syndrome

The research team, led by Shivani Mishra and corresponding author Royana Singh, recruited 125 fetal specimens from pregnancies that ended in loss, ultimately analyzing 118 samples after applying predefined exclusion criteria designed to guard against contamination and degraded tissue. The specimens, which included products of conception and fetal tissues such as skin, muscle, and cartilage obtained during autopsy, underwent DNA extraction and quantitative fluorescent PCR, a technique that amplifies short tandem repeat markers scattered across chromosomes 13, 18, 21, X, and Y. By measuring the relative quantity of fluorescent signals at these markers, QF-PCR can detect the most common whole-chromosome imbalances, the trisomies and monosomies that account for the majority of chromosomally abnormal miscarriages, often within a day or two of sample receipt.

The results were sobering but clinically rich. Of the 118 samples analyzed, QF-PCR identified aneuploidy in 36 cases, a detection rate of 30.5 percent. Twenty of these were monosomies, in which an entire chromosome is missing from the fetal genome, and sixteen were trisomies, in which an extra copy is present. The remaining 82 samples appeared normal by this rapid screen. That nearly one in three lost pregnancies carried a whole-chromosome imbalance confirms the central role of aneuploidy in early pregnancy failure, and it also carries a practical message for genetic counseling: when an aneuploidy is identified as the cause of a loss, the recurrence risk for future pregnancies is generally low, information that can meaningfully reduce anxiety for couples facing the aftermath of repeated loss.

Beyond the raw detection numbers, the study teased out clinical associations that matter for patient management. Maternal age showed a statistically significant relationship with the presence of chromosomal abnormalities, echoing decades of reproductive biology linking the aging oocyte to meiotic segregation errors. More intriguing was the finding of a weak but statistically significant negative correlation between gestational age and aneuploidy risk, with a correlation coefficient of −0.238 and a p-value of 0.008855. In other words, the earlier the loss, the more likely it was to be chromosomally abnormal, a pattern consistent with the idea that grossly imbalanced embryos tend to fail early in development, while losses later in gestation are more often driven by other mechanisms, including immunological, endocrine, thrombotic, and anatomical factors.

But QF-PCR has a well-known blind spot. It interrogates a limited set of chromosomes and cannot see submicroscopic copy number variations, the deletions and duplications of genomic segments too small to alter chromosome number but large enough to remove or duplicate genes. To peer beneath that resolution floor, the team selected a subset of 30 samples, stratified by their QF-PCR outcomes, and subjected them to array comparative genomic hybridization. In aCGH, differentially labeled fetal and reference DNA are co-hybridized to a microarray carrying hundreds of thousands of immobilized genomic probes, and the fluorescence ratio at each probe reveals whether the corresponding region is deleted or duplicated in the fetal genome. This technique can detect imbalances ranging from roughly 100 kilobases upward, an order of magnitude finer than conventional karyotyping.

The aCGH analysis proved its worth. Within the 30-sample cohort, the researchers identified clinically relevant copy number variations spanning the spectrum of pathogenicity, including pathogenic and likely pathogenic variants as well as variants of uncertain significance, the latter category reflecting regions whose dosage sensitivity has not yet been firmly established. Each variant was interpreted according to the joint guidelines of the American College of Medical Genetics and the Clinical Genome Resource, the standard framework that weighs factors such as gene content, inheritance pattern, and overlap with established disease loci before assigning a clinical classification.

Among the genes caught in deleted or duplicated segments were several with compelling biological narratives. CFHR3, a member of the complement factor H-related gene family, participates in the regulation of the complement cascade, the arm of innate immunity whose dysregulation has been implicated in inflammatory damage at the maternal-fetal interface. TNFRSF4 encodes a tumor necrosis factor receptor superfamily member with roles in immune cell signaling and tolerance. UGT2B17 belongs to the uridine diphosphate glucuronosyltransferase family, a set of metabolic detoxification enzymes whose variation has previously been linked to recurrent miscarriage, possibly through altered clearance of environmental and endogenous compounds. CD24 and MSR1 are involved in immune signaling and macrophage scavenger function, respectively, while the pregnancy-specific glycoprotein gene family, or PSG genes, is expressed almost exclusively in the placenta and is thought to modulate maternal immune tolerance of the fetus.

To move from gene lists to mechanism, the authors turned the implicated genes loose on a battery of bioinformatics tools. Using FunRich and WebGestalt for functional annotation, KEGG for pathway enrichment, and STRING for protein-protein interaction network construction, the team asked what biological themes united the disrupted loci. The answer converged on a coherent set of processes: immune-inflammatory signaling, endocrine regulation, lipid metabolism, extracellular matrix remodeling, and placental development. The involvement of TNF receptor signaling, MAPK cascades, and interleukin-1-related pathways emerged from the network analyses, weaving the copy number variations into the same immunological tapestry that independent studies have implicated in unexplained recurrent loss, including work on maternal B cell signaling and natural killer cell-mediated immunopathology.

The authors are careful, appropriately so, to frame the pathway findings as exploratory. The cohort of 30 microarray samples is modest, and several of the variants of uncertain significance may prove benign as genomic databases mature. The statistical associations between individual CNVs and miscarriage phenotypes will require validation in larger, well-powered cohorts with matched controls before they can inform clinical decision-making. Still, the architectural message of the study is clear: sequential testing with QF-PCR followed by aCGH captures abnormalities that neither method detects alone, and it does so at a fraction of the cost and turnaround time of broader approaches such as whole-genome sequencing.

That message lands at a moment of ferment in reproductive genetics. European Society of Human Reproduction and Embryology guidelines define recurrent pregnancy loss as two or more consecutive losses, and professional societies have been wrestling with the optimal diagnostic workup of lost pregnancy tissue for years. Previous studies comparing karyotyping with molecular methods have shown that conventional cytogenetics suffers from culture failure and maternal cell contamination, problems that DNA-based methods largely sidestep. The Banaras Hindu University team’s approach, anchored in a real clinical diagnostic laboratory serving a population with limited access to advanced genomic testing, demonstrates that a tiered molecular protocol is feasible and productive outside of well-funded Western centers.

For couples enduring the grief of repeated loss, the study’s findings translate into a concrete recommendation worth discussing with a genetic counselor: comprehensive cytogenetic analysis of lost pregnancy tissue is not merely an academic exercise. Identifying an aneuploidy or a pathogenic copy number variant can close the diagnostic loop, refine recurrence risk estimates, and in some cases guide the management of subsequent pregnancies, including targeted prenatal or preimplantation genetic testing. Conversely, a normal molecular karyotype redirects the clinical search toward the non-genetic contributors, from antiphospholipid syndrome to uterine anomalies.

The work also adds to a growing map of the genomic landscape of pregnancy failure, in which the PSG gene cluster on chromosome 19, the complement factor H-related locus, and immune receptor genes recur across independent cohorts. As genome-wide datasets accumulate and functional studies test the dosage sensitivity of these loci, variants of uncertain significance will gradually be reclassified, and the exploratory pathway signals reported here may harden into causal mechanisms. Until then, the study stands as both a practical diagnostic template and a hypothesis-generating catalog of the fragile genetic architecture underlying one of medicine’s most quietly devastating problems.